港股異動 | 信達生物(1801.HK)大漲7.49% 信迪利單抗一線治療胃癌新適應症上市申請獲受理
格隆匯11月9日丨信達生物(1801.HK)大漲7.49%,暫錄三連漲,區間漲幅約13%,報76.1港元,總市值1111億港元。信達生物上週發佈公吿,國家藥監局正式受理創新PD-1抑制劑信迪利單抗聯合化療(奧沙利鉑及卡培他濱)新適應症的上市申請,用於一線治療不可切除局部晚期、複發性或轉移性胃或胃食管交界處腺癌。據信達生物發佈的2021年第三季度銷售數據顯示,今年第三季度,信迪利單抗注射液銷售收入約為8億元,產品銷售量保持逐季增長的良好態勢。結合信達生物2021年第一、二季度的業績數據來看,信迪利單抗今年前三季度銷售額超過22億元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.